Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Gilead: Stop Blocking Access to Hepatitis C Treatment

On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.

Published
3 hours ago
From
Treatment Action Group
High Cure Rates Will Not Curb Hepatitis C, Expert Warns

Even with new drug combinations that have cure rates nearing 100%, the fight against the hepatitis C virus is not over, according to one global expert. "I believe that an infection present in 130 million to 170 million individuals cannot be eradicated with antiviral therapies. It's just not possible," said Jean-Michel Pawlotsky, MD, from Henri Mondor University Hospital in Créteil, France.

Published
3 hours ago
From
Medscape
Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment.

Published
3 hours ago
From
Hep C Coalition
Egypt opens first factory for locally produced Sovaldi

Egypt's health minister said Hepatitis C is "one of the most dangerous threats to Egypt", on Sunday during the opening ceremony of a factory for the local production of Hepatitis C medication Sovaldi.

Published
3 hours ago
From
News Egypt
Gilead first-quarter profit doubles on strong hepatitis C drug sales

Gilead Sciences Inc on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates. Gilead signaled that, with its hepatitis C franchise established, it is a good time for the company to consider business development opportunities. "We want to stick very closely to therapeutic areas we are in today," Gilead Chief Operating Officer John Milligan said on a conference call.

Published
3 hours ago
From
Reuters
Joint Pain a Major Issue in Chronic HCV Infection

Patient-reported joint pain is prevalent in those with chronic monoinfection with hepatitis C virus (HCV) or monoinfection with immunodeficiency virus (HIV), as well as in patients with HIV/HCV coinfection, according to a study published online in BMC Musculoskeletal Disorders on April 19, 2015. But chronic HCV patients report more arthralgia.

Published
3 hours ago
From
MedPage Today
Another study confirms detrimental effects of delaying hepatitis C treatment

Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical

Published
3 hours ago
By
Liz Highleyman
When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

More than 70% of people with chronic genotype 1 hepatitis C who did not achieve a sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12

Published
01 May 2015
By
Liz Highleyman
Sofosbuvir-based treatment safe and effective in advanced kidney disease

Sofosbuvir-based direct-acting antiviral therapy for hepatitis C can be used safely and effectively in people with very advanced kidney disease, including people on dialysis, according to the

Published
30 April 2015
By
Keith Alcorn
Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease

The once-daily combination of grazoprevir and elbasvir cured hepatitis C in 99% of people with advanced chronic kidney disease, researchers reported at the International Liver Congress last

Published
28 April 2015
By
Keith Alcorn
← First12345...165Next →

Filter by country